[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575587":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":48,"collaborators":31,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":31,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":31,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":31,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","Fruquintinib Combined with Standard Chemotherapy",[13],"Drug: Fruquintinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Fruquintinib","Fruquinitinib: Take 4 mg QD for 2 weeks and stop for 1 week, every 3 weeks for a cycle; Standard chemotherapy: The selection of drugs is recommended by the 2024CSCO Guidelines for the Diagnosis and Treatment of Gastric Cancer, including SOX, XLOX or S-1, and the treatment cycle is one every 3 weeks",[9],[21],"HMPL-013",[23],{"name":24,"affiliation":25,"role":26},"Fei Ma, M.D.","Working relationship","PRINCIPAL_INVESTIGATOR",[28],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+8613703923592",null,"mafeizzu@outlook.com",[34],{"facility":5,"status":35,"city":36,"state":31,"zip":31,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Zhengzhou","China","CN",{"type":40,"coordinates":41},"Point",[42,43],113.64861,34.75778,{"lat":43,"lon":42},[46],{"name":47,"role":29,"phone":31,"phoneExt":31,"email":31},"Fei Ma",{"type":49,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100575587","phase-2-a-study-of-fruquintinib-plus-chemotherapy-for-postoperative-treatment-of-her2-negative-gastric-cancer-with-poor-trg-100575587",false,"NCT06774222","A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG","A Phase II, Single-Arm, Single-Center Study of Fruquintinib Combined With Standard Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer Patients With Poor Tumor Regression Grade.","Inclusion Criteria:\n\n1. Fully understand the study and voluntarily sign the informed consent form;\n2. Age between 18 and 75 years;\n3. Histologically confirmed resectable or potentially resectable locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma;\n4. Tumor Regression Grade (TRG) 2 or 3 after preoperative adjuvant therapy;\n5. R0 resection after neoadjuvant chemotherapy;\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n7. Life expectancy of at least 2 years;\n8. No prior anti-cancer treatment received;\n9. Good compliance and cooperation with follow-up.\n\nExclusion Criteria:\n\n1. Inability to comply with the study protocol or procedures;\n2. History of prior gastric cancer surgery;\n3. Contraindications to surgical treatment and chemotherapy or physical condition and organ function that do not allow for major abdominal surgery;\n4. Distant metastasis to organs other than the liver, such as lung, brain, and bone;\n5. Known HER2-positive patients;\n6. Uncontrolled hypertension despite medication prior to enrollment;\n7. Poorly controlled diabetes despite medication prior to enrollment;\n8. Urine routine indicating proteinuria ≥2+, and a 24-hour urine protein quantification \\>1.0g;\n9. Presence of conditions requiring intervention such as bleeding, perforation, or obstruction prior to enrollment;\n10. Patients deemed ineligible for this study by the investigator.","ALL","18 Years","75 Years",{"count":61,"type":62},69,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","Given that a significant proportion of locally advanced gastric cancer patients still die from tumor recurrence after surgery, with long-term therapeutic outcomes stagnating and difficult to further improve, especially for patients with poor tumor regression grade (TRG) after surgery, this study aims to explore a new model of adjuvant therapy by conducting research on the use of Fruquintinib in combination with standard chemotherapy for postoperative treatment of HER2-negative gastric cancer patients with poor TRG, in order to bring greater survival benefits to patients.",[68],"Gastric\u002FGastroesophageal Junction Adenocarcinoma","2025-01-13",{"date":71,"type":72},"2025-01-14","ACTUAL",{"date":74,"type":72},"2023-09-12",{"date":76,"type":62},"2026-12-31",{"name":5,"class":6},1]